Brainstorm Days Payables Outstanding vs Capex To Revenue Analysis

BCLI Stock

USD 1.61 0.03 1.90%

Brainstorm Cell financial indicator trend analysis is way more than just evaluating Brainstorm Cell Ther prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Brainstorm Cell Ther is a good investment. Please check the relationship between Brainstorm Cell Days Payables Outstanding and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Days Payables Outstanding vs Capex To Revenue

Days Payables Outstanding vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Brainstorm Cell Ther Days Payables Outstanding account and Capex To Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Brainstorm Cell's Days Payables Outstanding and Capex To Revenue is -0.06. Overlapping area represents the amount of variation of Days Payables Outstanding that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Brainstorm Cell Therapeutics, assuming nothing else is changed. The correlation between historical values of Brainstorm Cell's Days Payables Outstanding and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Payables Outstanding of Brainstorm Cell Therapeutics are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Days Payables Outstanding i.e., Brainstorm Cell's Days Payables Outstanding and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.06

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Days Payables Outstanding

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Brainstorm Cell's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Brainstorm Cell Ther current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

The Brainstorm Cell's current Selling General Administrative is estimated to increase to about 11.2 M, while Issuance Of Capital Stock is projected to decrease to under 13.7 M.

Brainstorm Cell fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant And Equipment Net	Property Plant And Equipment Gross	Current Deferred Revenue	Accounts Payable	Non Currrent Assets Other	Net Receivables
Total Assets		0.89	-0.18	0.36	0.9	-0.92	-0.28	0.94	0.77	0.99	0.35	0.29	0.61	0.55	0.4	0.5	0.99	0.89	-0.28	0.48	0.76	0.55	-0.24	0.15	-0.06	-0.11
Short Long Term Debt Total	0.89		-0.31	0.4	0.76	-0.79	-0.27	0.84	0.81	0.85	0.29	0.21	0.56	0.42	0.36	0.55	0.85	0.85	-0.46	0.51	0.81	0.49	-0.16	0.23	-0.11	-0.04
Other Current Liab	-0.18	-0.31		0.18	-0.34	0.19	-0.69	-0.17	0.03	-0.22	0.65	0.72	-0.02	0.05	0.66	0.16	-0.23	-0.19	-0.26	0.31	0.03	0.46	-0.33	0.16	0.0	-0.15
Total Current Liabilities	0.36	0.4	0.18		-0.07	-0.23	-0.56	0.33	0.67	0.23	0.51	0.49	0.43	0.44	0.52	0.98	0.27	0.4	-0.29	0.57	0.66	0.56	-0.63	0.96	0.03	0.43
Total Stockholder Equity	0.9	0.76	-0.34	-0.07		-0.86	0.03	0.83	0.47	0.95	0.11	0.01	0.46	0.39	0.12	0.08	0.94	0.76	-0.18	0.27	0.47	0.26	0.08	-0.27	-0.04	-0.25
Net Debt	-0.92	-0.79	0.19	-0.23	-0.86		0.18	-0.99	-0.69	-0.92	-0.17	-0.18	-0.46	-0.48	-0.31	-0.38	-0.92	-0.88	0.14	-0.24	-0.68	-0.53	0.21	-0.01	0.09	0.21
Retained Earnings	-0.28	-0.27	-0.69	-0.56	0.03	0.18		-0.27	-0.66	-0.17	-0.82	-0.99	-0.39	-0.35	-0.99	-0.63	-0.17	-0.23	0.35	-0.61	-0.66	-0.88	0.69	-0.47	0.04	0.26
Cash	0.94	0.84	-0.17	0.33	0.83	-0.99	-0.27		0.79	0.92	0.21	0.26	0.49	0.48	0.39	0.49	0.91	0.89	-0.16	0.3	0.79	0.62	-0.3	0.11	-0.12	-0.21
Non Current Assets Total	0.77	0.81	0.03	0.67	0.47	-0.69	-0.66	0.79		0.67	0.45	0.61	0.59	0.5	0.71	0.81	0.67	0.7	-0.23	0.51	0.99	0.85	-0.63	0.5	-0.07	-0.19
Cash And Short Term Investments	0.99	0.85	-0.22	0.23	0.95	-0.92	-0.17	0.92	0.67		0.28	0.19	0.54	0.48	0.31	0.37	1.0	0.87	-0.25	0.42	0.66	0.46	-0.12	0.02	-0.08	-0.16
Common Stock Total Equity	0.35	0.29	0.65	0.51	0.11	-0.17	-0.82	0.21	0.45	0.28		0.84	0.45	0.42	0.83	0.52	0.3	0.3	-0.68	0.85	0.43	0.6	-0.33	0.41	0.13	0.03
Common Stock Shares Outstanding	0.29	0.21	0.72	0.49	0.01	-0.18	-0.99	0.26	0.61	0.19	0.84		0.39	0.37	0.99	0.56	0.19	0.2	-0.32	0.6	0.6	0.86	-0.67	0.4	-0.01	-0.3
Non Current Liabilities Total	0.61	0.56	-0.02	0.43	0.46	-0.46	-0.39	0.49	0.59	0.54	0.45	0.39		0.9	0.43	0.48	0.58	0.49	-0.3	0.53	0.51	0.4	-0.4	0.28	0.5	0.14
Other Current Assets	0.55	0.42	0.05	0.44	0.39	-0.48	-0.35	0.48	0.5	0.48	0.42	0.37	0.9		0.39	0.47	0.52	0.38	-0.24	0.48	0.42	0.41	-0.41	0.3	0.55	0.19
Other Stockholder Equity	0.4	0.36	0.66	0.52	0.12	-0.31	-0.99	0.39	0.71	0.31	0.83	0.99	0.43	0.39		0.61	0.31	0.34	-0.37	0.62	0.71	0.91	-0.66	0.4	-0.04	-0.32
Total Liab	0.5	0.55	0.16	0.98	0.08	-0.38	-0.63	0.49	0.81	0.37	0.52	0.56	0.48	0.47	0.61		0.4	0.51	-0.29	0.58	0.8	0.69	-0.68	0.9	-0.04	0.29
Total Current Assets	0.99	0.85	-0.23	0.27	0.94	-0.92	-0.17	0.91	0.67	1.0	0.3	0.19	0.58	0.52	0.31	0.4		0.87	-0.28	0.44	0.66	0.45	-0.14	0.07	-0.05	-0.09
Short Term Debt	0.89	0.85	-0.19	0.4	0.76	-0.88	-0.23	0.89	0.7	0.87	0.3	0.2	0.49	0.38	0.34	0.51	0.87		-0.37	0.38	0.7	0.46	-0.16	0.19	-0.08	-0.04
Intangible Assets	-0.28	-0.46	-0.26	-0.29	-0.18	0.14	0.35	-0.16	-0.23	-0.25	-0.68	-0.32	-0.3	-0.24	-0.37	-0.29	-0.28	-0.37		-0.74	-0.21	-0.17	-0.21	-0.23	-0.12	-0.27
Common Stock	0.48	0.51	0.31	0.57	0.27	-0.24	-0.61	0.3	0.51	0.42	0.85	0.6	0.53	0.48	0.62	0.58	0.44	0.38	-0.74		0.48	0.44	-0.18	0.46	0.15	0.18
Property Plant And Equipment Net	0.76	0.81	0.03	0.66	0.47	-0.68	-0.66	0.79	0.99	0.66	0.43	0.6	0.51	0.42	0.71	0.8	0.66	0.7	-0.21	0.48		0.87	-0.65	0.5	-0.21	-0.2
Property Plant And Equipment Gross	0.55	0.49	0.46	0.56	0.26	-0.53	-0.88	0.62	0.85	0.46	0.6	0.86	0.4	0.41	0.91	0.69	0.45	0.46	-0.17	0.44	0.87		-0.76	0.42	-0.18	-0.37
Current Deferred Revenue	-0.24	-0.16	-0.33	-0.63	0.08	0.21	0.69	-0.3	-0.63	-0.12	-0.33	-0.67	-0.4	-0.41	-0.66	-0.68	-0.14	-0.16	-0.21	-0.18	-0.65	-0.76		-0.61	0.2	0.02
Accounts Payable	0.15	0.23	0.16	0.96	-0.27	-0.01	-0.47	0.11	0.5	0.02	0.41	0.4	0.28	0.3	0.4	0.9	0.07	0.19	-0.23	0.46	0.5	0.42	-0.61		-0.07	0.57
Non Currrent Assets Other	-0.06	-0.11	0.0	0.03	-0.04	0.09	0.04	-0.12	-0.07	-0.08	0.13	-0.01	0.5	0.55	-0.04	-0.04	-0.05	-0.08	-0.12	0.15	-0.21	-0.18	0.2	-0.07		0.08
Net Receivables	-0.11	-0.04	-0.15	0.43	-0.25	0.21	0.26	-0.21	-0.19	-0.16	0.03	-0.3	0.14	0.19	-0.32	0.29	-0.09	-0.04	-0.27	0.18	-0.2	-0.37	0.02	0.57	0.08

Click cells to compare fundamentals

Brainstorm Cell Account Relationship Matchups

Brainstorm Cell fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.5M	51.3M	29.3M	8.5M	4.2M	4.0M
Other Current Liab	1M	506K	1.2M	1.1M	2.8M	3.0M
Total Current Liabilities	17.7M	11.2M	6.3M	8.8M	7.8M	4.2M
Total Stockholder Equity	(12.2M)	35.5M	19.3M	(3.0M)	(4.9M)	(4.6M)
Net Debt	1.8M	(30.6M)	(13.8M)	3.3M	(628K)	(659.4K)
Retained Earnings	(117.3M)	(149.1M)	(173.5M)	(197.8M)	(215.0M)	(204.3M)
Cash	536K	37.8M	18.9M	772K	1.3M	1.2M
Non Current Assets Total	3.2M	8.0M	6.0M	5.3M	2.3M	1.6M
Cash And Short Term Investments	569K	41.9M	22.1M	3.0M	1.3M	1.2M
Common Stock Shares Outstanding	21.9M	29.8M	36.2M	36.5M	43.1M	45.2M
Liabilities And Stockholders Equity	6.5M	51.3M	29.3M	8.5M	4.2M	4.0M
Non Current Liabilities Total	1.1M	4.6M	3.6M	2.7M	1.3M	1.3M
Other Current Assets	1.2M	432K	984K	1.1M	548K	306.8K
Other Stockholder Equity	105.0M	184.5M	192.9M	194.8M	210.1M	220.6M
Total Liab	18.8M	15.8M	9.9M	11.5M	9.1M	4.9M
Total Current Assets	3.4M	43.2M	23.3M	3.1M	1.9M	1.8M
Property Plant And Equipment Net	3.1M	8.0M	6.0M	5.3M	2.1M	1.6M
Property Plant And Equipment Gross	3.1M	8.0M	8.2M	5.3M	6.1M	6.4M
Accounts Payable	15.4M	5.4M	3.7M	6.2M	5.0M	2.7M
Non Currrent Assets Other	32.0K	26.0K	27.0K	23.0K	207K	137.3K
Net Receivables	2.4M	304K	86K	91K	51K	48.5K
Other Assets	32K	26K	27K	23K	26.5K	25.1K
Property Plant Equipment	3.1M	8.0M	6.0M	5.3M	6.1M	6.4M
Net Tangible Assets	(12.2M)	35.5M	19.3M	(3.0M)	(3.5M)	(3.3M)
Retained Earnings Total Equity	(94.0M)	(117.3M)	(149.1M)	(173.5M)	(156.2M)	(148.4M)
Short Term Investments	33K	4.1M	3.2M	2.2M	2.5M	4.9M
Capital Surpluse	94.6M	105.0M	184.7M	193.0M	221.9M	233.0M
Net Invested Capital	(12.2M)	35.5M	19.3M	(3.0M)	(3.5M)	(3.3M)
Net Working Capital	(14.3M)	32.0M	17.0M	(5.7M)	(6.5M)	(6.2M)

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:

How To Invest In Brainstorm

Details

Is Brainstorm Stock a good investment?

Details

What is Brainstorm Cell's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.45)

Return On Assets

(1.78)

Return On Equity

(11.22)

The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Brainstorm Days Payables Outstanding vs Capex To Revenue Analysis

Days Payables Outstanding vs Capex To Revenue

Days Payables Outstanding vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Days Payables Outstanding

Capex To Revenue

Brainstorm Cell fundamental ratios Correlations

Brainstorm Cell Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Brainstorm Cell fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Non Current Assets Total
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Liab	+ 0.98	Total Current Liabilities

Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Total Current Assets	- 0.92	Net Debt
Cash And Short Term Investments	- 0.92	Net Debt
Net Debt	- 0.92	Total Assets